Pharma DECODED
Previous edition: 11 Apr 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Lisata wins FDA orphan drug status for bone cancer candidate
The orphan drug designation adds to previous rare paediatric disease and fast-track designations for the drug.
The US Food and Drug Administration (FDA) has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) for the treatment of osteosarcoma, a rare type of blood cancer.
The US-based pharma company will be eligible for tax credits for qualifying US-based clinical trials and, pending approval, seven years of market exclusivity in the designated indication.
Orphan drug designations are handed out by the FDA for drugs or biologics that target diseases that affect fewer than 200,000 people in the US.
Osteosarcoma is most often diagnosed in children and young adults, accounting for 2% of all cancers in those aged up to 14 years old, and 3% of all cancers in teens aged 15-19 years old.
LSTA1 is designed to increase the efficacy of co-administered anti-cancer drugs penetrating solid tumours. The cyclic peptide activates the CendR uptake pathway that allows bounded medicine to accumulate in the tumour. Lisata says its compound can also modify the tumour microenvironment to make tumours more susceptible to immunotherapies.
The orphan drug designation follows an FDA rare paediatric disease designation earlier this month and fast track designation awarded in 2022. The former could point to the company receiving a priority voucher upon approval while the latter could potentially expedite development and review. Also with orphan drug status for osteosarcoma is Radiopharm Theranostics’s monoclonal antibody DUNP19. The Australian biotech received the designation in September 2022.
Lisata is also targeting other cancers with its asset. LSTA1 has FDA orphan drug status for glioblastoma multiform treatment, as well as FDA and European orphan status for pancreatic cancer.
According to analysis by GlobalData, the drug is being evaluated across several Phase II clinical trials, including the Phase II BOLSTER study (NCT05712356) for solid tumour treatment, the Phase II ASCEND trial for pancreatic cancer treatment, and a Phase II trial for patients with newly diagnosed glioblastoma multiforme (GBM).
“We are thrilled to have received another favourable regulatory designation from the FDA. Osteosarcoma, while rare, is a type of bone cancer that is often associated with high morbidity, early metastasis, rapid progression, and poor prognosis. Receiving an orphan drug designation from the FDA is an important milestone as we plan for future clinical expansion of LSTA1,” said Lisata’s chief medical officer, Dr Kristen Buck in a 9 April press release.
Latest news
Novartis plans to axe 680 employees
The current downsizing is separate from a company restructuring programme, which could see the dismissal of up to 8,000 employees.
ACC 24: EMPACT-MI study fails to meet primary endpoint
Data from this study demonstrating improvement in HF hospitalisation rates is consistent with studies in populations using SGLT-2Is in T2D and CKD.
Drug delivery innovations push forth women's health
From nanoparticles to transdermal patches, Pharmaceutical Technology takes a look at the latest in drug delivery technologies for women's health.
Syros's tamibarotene gains FDA fast track status for AML treatment
A tamibarotene regimen demonstrated a 100% CR/CRi rate in a Phase II trial.
Ocugen to initiate Phase III trial of gene therapy for retinitis pigmentosa
Ocugen will soon be initiating a Phase III trial of its gene therapy candidate OCU400 for retinitis pigmentosa (RP). The…
Signati kicks off trial investigating quicker vasectomy device
Signati aims to take the next big step in vasectomies by offering men a safer and quicker option for family planning.
Myriad's GeneSight test proves effective in new study data
The 21,000 subject-study demonstrated a reduction in psychiatric-related hospitalisations following the test.
11th Annual Clinical Trials in Oncology West Coast 2024
The upcoming Clinical Trials In Oncology West Coast 2024 will bring together pharma and biotech experts to discuss clinical-stage cancer therapy development.
In our previous edition
Pharma Decoded
Oryzon wins FDA approval to begin SCLC treatment trial
10 Apr 2024
Pharma Decoded
J&J and Legend's Carvykti scores early line approval for MM by FDA
09 Apr 2024
Pharma Decoded
FDA approves Daiichi Sankyo-AstraZeneca's Enhertu for solid tumours
08 Apr 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Technology
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer